Immunomodulatory Properties of Pancreatic Islet-Derived Stem Cells Co-Cultured with T cells: Does It Contribute to the Pathogenesis of Type 1 Diabetes?

A. E. Sariboyaci; P. C. Demircan; G. Gacar; Z. S. Unal; G. Erman; E. Karaoz

doi:10.1055/s-0034-1367004

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2014; 122(03): 179-189
DOI: 10.1055/s-0034-1367004

Article

Immunomodulatory Properties of Pancreatic Islet-Derived Stem Cells Co-Cultured with T cells: Does It Contribute to the Pathogenesis of Type 1 Diabetes?

A. E. Sariboyaci

¹Center for Stem Cell and Gene Therapies Research and Practice, Institute of Health Sciences, Stem Cell Department, Kocaeli University, Kocaeli, Turkey

,

P. C. Demircan

¹Center for Stem Cell and Gene Therapies Research and Practice, Institute of Health Sciences, Stem Cell Department, Kocaeli University, Kocaeli, Turkey

,

G. Gacar

¹Center for Stem Cell and Gene Therapies Research and Practice, Institute of Health Sciences, Stem Cell Department, Kocaeli University, Kocaeli, Turkey

,

Z. S. Unal

¹Center for Stem Cell and Gene Therapies Research and Practice, Institute of Health Sciences, Stem Cell Department, Kocaeli University, Kocaeli, Turkey

,

G. Erman

¹Center for Stem Cell and Gene Therapies Research and Practice, Institute of Health Sciences, Stem Cell Department, Kocaeli University, Kocaeli, Turkey

,

E. Karaoz

¹Center for Stem Cell and Gene Therapies Research and Practice, Institute of Health Sciences, Stem Cell Department, Kocaeli University, Kocaeli, Turkey

› Author Affiliations

Abstract

Background:

Previously, we isolated stem cells from rat pancreatic islets (rPI-SCs) with similar characteristics of bone-marrow derived-mesenchymal stem cells (MSCs). We aimed to investigate the immunomodulatory effects of them on stimulated T-cells.

Methods:

Following in vitro co-culturing directly and indirectly, the response of T-cells stimulated by concanavalin-A and immunosuppressive activity of rPI-SCs were evaluated by analysing in terms of cell viability, proliferation and apoptosis, cell cycle, differentiation of Treg, cytokines and some regulatory factors produced from T and SCs.

Results:

Our results have firstly demonstrated that rPI-SCs like MSCs could regulate stimulated T-cell responses by altering their cell-cycle and cytokine profile, inhibiting the cell proliferation, and inducing the apoptosis and differentiation of Treg. Direct and indirect in vitro co-cultures of rPI-SCs with stimulated T-cells showed immunosuppressive effects.

Conclusion:

Therefore, we are introducing a novel type of stem cell with immunomodulatory properties. On the other hand, it is questionable why PI-SCs cannot protect the insulin producing cells from attacks of autoreactive T-cells in the developing of type1 diabetes. For this purpose, further molecular researches in vitro and in vivo are needed to clarify why PI-SCs may not suppress attacks of autoreactive-immune-cells towards PIs. PI-SCs from diseased people should be compared with pancreas of healthy ones at both genomic and proteomic levels.

Key words

characterization - immunosuppression - pancreatic islets - stem cells

Full Text

References

References
1 Xu YX, Chen L, Wang R et al. Mesenchymal stem cell therapy for diabetes through paracrine mechanisms. Med Hypotheses 2008; 71: 390-393
2 Ichim TE, Alexandrescu DT, Solano F et al. Mesenchymal stem cells as anti-inflammatories: Implications for treatment of Duchenne muscular dystrophy. Cell Immunol 2010; 260: 75-82
3 Gnecchi M, He HM, Noiseux N et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006; 20: 661-669
4 Karaoz E, Ayhan S, Gacar G et al. Isolation and characterization of stem cells from pancreatic islet: pluripotency, differentiation potential and ultrastructural characteristics. Cytotherapy 2010; 12: 288-302
5 Karaoz E, Genc ZS, Demircan PC et al. Protection of rat pancreatic islet function and viability by coculture with rat bone marrow-derived mesenchymal stem cells. Cell Death Dis 2010; 1: 1-8
6 Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplant 2006; 81: 1390-1397
7 Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48
8 Yanez R, Lamana ML, Garcia-Castro J et al. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006; 24: 2582-2591
9 Mathew JM, Carreno M, Fuller L et al. Modulatory effects of human donor bone marrow cells on allogeneic cellular immune responses. Transplant 1997; 63: 686-692
10 Tyndall A, Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplant 2009; 43: 821-828
11 Gerdoni E, Gallo B, Casazza S et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007; 61: 219-227
12 Zappia E, Casazza S, Pedemonte E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106: 1755-1761
13 Honczarenko M, Le Y, Swierkowski M et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24: 1030-1041
14 Dazzi F, Marelli-Berg FM. Mesenchymal stem cells for graft-versus-host disease: Close encounters with T cells. Eur J Immunol 2008; 38: 1479-1482
15 Karaoz E, Aksoy A, Ayhan S et al. Characterization of mesenchymal stem cells from rat bone marrow: ultrastructural properties, differentiation potential and immunophenotypic markers. Histochem Cell Biol 2009; 132: 533-546
16 Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317
17 Demircan PC, Sariboyaci AE, Unal ZS et al. Immunoregulatory effects of human dental pulp-derived stem cells on T cells: comparison of transwell co-culture and mixed lymphocyte reaction systems. Cytotherapy 2011; 13: 1205-1220
18 Zulewski H, Abraham EJ, Gerlach MJ et al. Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 2001; 50: 521-533
19 Gershengorn MC, Geras-Raaka E, Hardikar AA et al. Are better islet cell precursors generated by epithelial-to-mesenchymal transition?. Cell Cycle 2005; 4: 380-382
20 Zhang L, Hong TP, Hu J et al. Nestin-positive progenitor cells isolated from human fetal pancreas have phenotypic markers identical to mesenchymal stem cells. World J Gastroenterol 2005; 11: 2906-2911
21 Eberhardt M, Salmon P, von Mach MA et al. Multipotential nestin and Isl-1 positive mesenchymal stem cells isolated from human pancreatic islets. Biochem Biophys Res Commun 2006; 345: 1167-1176
22 Atouf F, Park CH, Pechhold K et al. No evidence for mouse pancreatic beta-cell epithelial-mesenchymal transition in vitro. Diabetes 2007; 56: 699-702
23 Chase LG, Ulloa-Montoya F, Kidder BL et al. Islet-derived fibroblast-like cells are not derived via epithelial-mesenchymal transition from Pdx-1 or insulin-positive cells. Diabetes 2007; 56: 3-7
24 Davani B, Ikonomou L, Raaka BM et al. Human islet-derived precursor cells are mesenchymal stromal cells that differentiate and mature to hormone-expressing cells in vivo. Stem Cells 2007; 25: 3215-3222
25 Ghannam S, Bouffi C, Djouad F et al. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 2010; 15: 1-7
26 van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology 2006; 45: 1187-1193
27 Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729
28 Tabera S, Perez-Simon JA, Diez-Campelo M et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematol Hematol J 2008; 93: 1301-1309
29 Jiang XX, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126
30 Le Blanc K, Tammik L, Sundberg B et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11-20
31 Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003; 75: 389-397
32 Ye Z, Wang Y, Xie HY et al. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4(+)CD25(+) regulatory T cells. Hepatobiliary Pancreat Dis Int 2008; 7: 608-614
33 Plumas J, Chaperot L, Richard MJ et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19: 1597-1604
34 Benvenuto F, Ferrari S, Gerdoni E et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 2007; 25: 1753-1760
35 Raffaghello L, Bianchi G, Bertolotto M et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: A model for neutrophil preservation in the bone marrow niche. Stem Cells 2008; 26: 151-162
36 Ramasamy R, Lam EWF, Soeiro I et al. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 2007; 21: 304-310
37 Glennie S, Soeiro I, Dyson PJ et al. Bone marrow mesenchymal stem cefls induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827
38 Corcione A, Benvenuto F, Ferretti E et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372
39 Le Blanc K, Rasmusson I, Gotherstrom C et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004; 60: 307-315
40 Groh ME, Maitra B, Szekely E et al. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005; 33: 928-934
41 Tsimberidou AM, Giles FJ. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther 2002; 2: 277-286
42 Yang-Hee K, Wee YM, Choi MY et al. Interleukin (IL)-10 Induced by CD11b + Cells and IL-10-Activated Regulatory T Cells Play a Role in Immune Modulation of Mesenchymal Stem Cells in Rat Islet Allografts. Mol Med 2011; 17: 697-708
43 Zhou HP, Jin ZX, Liu JC et al. Mesenchymal stem cells might be used to induce tolerance in heart transplantation. Med Hypotheses 2008; 70: 785-787
44 van den Brink MRM, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2002; 2: 273-281
45 Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822
46 Bruner RJ, Farag SS. Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Semin Oncol 2003; 30: 509-519
47 English K, Ryan JM, Tobin L et al. Cell contact, prostaglandin E-2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4(+)CD25(High)forkhead box P3(+) regulatory T cells. Clin Exp Immunol 2009; 156: 149-160
48 Zheng SG, Wang JH, Koss MN et al. CD4(+) and CD8(+) regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol 2004; 172: 1531-1539
49 Weiss ML, Anderson C, Medicetty S et al. Immune properties of human umbilical cord Wharton’s jelly-derived cells. Stem Cells 2008; 26: 2865-2874
50 Ren GW, Zhao X, Zhang LY et al. Inflammatory Cytokine-Induced Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 in Mesenchymal Stem Cells Are Critical for Immunosuppression. J Immunol 2010; 184: 2321-2328
51 Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843
52 Roncarolo MG, Gregori S, Battaglia M et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 21: 28-50
53 Fontenot JD, Rasmussen JP, Gavin MA et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-1151
54 Shevach EM. CD4(+)CD25(+) suppressor T cells: More questions than answers. Nat Rev Immunol 2002; 2: 389-400
55 Sakaguchi S. Naturally arising CD4(+) regulatory T cells for immunologic self-tolerance and negative control of immune responses. Ann Rev Immunol 2004; 22: 531-562
56 Chen X, McClurg A, Zhou GQ et al. Chondrogenic differentiation alters the immunosuppressive property of bone marrow-derived mesenchymal stem cells, and the effect is partially due to the upregulated expression of B7 molecules. Stem Cells 2007; 25: 364-370
57 Suva D, Passweg J, Arnaudeau S et al. In vitro activated human T lymphocytes very efficiently attach to allogenic multipotent mesenchymal stromal cells and transmigrate under them. J Cellular Physiol 2008; 214: 588-594
58 Uccelli A, Mancardi G, Chiesa S. Is there a role for mesenchymal stem cells in autoimmune diseases?. Autoimmunity 2008; 41: 592-595